Difference between revisions of "Anagrelide (Agrylin)"
Jump to navigation
Jump to search
(updated content) |
m (categories) |
||
| Line 16: | Line 16: | ||
==References== | ==References== | ||
<references/> | <references/> | ||
| + | |||
| + | [[Category:Drug index]] | ||
| + | [[Category:Hematology medications]] | ||
| + | [[Category:Phosphodiesterase inhibitors]] | ||
Revision as of 22:48, 7 October 2012
Also known as Xagrid.
General information
Class/mechanism: Interferes with maturation of platelets from megakaryocytes, phosphodiesterase inhibitor.[1][2]
Route: PO
Extravasation: n/a
- Example of usage: Anagrelide (Agrylin) 0.5 mg PO 4 times per day or 1 mg PO twice per day, titrate to the lowest effective dose to maintain platelets below 600,000, maximum increase in dose of 0.5 mg/day every week (max dose: 10 mg/day, 2.5 mg in a single dose)
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Patient drug information
- Anagrelide (Agrylin) patient drug information (Chemocare)[3]
- Anagrelide (Agrylin) patient drug information (UpToDate)[4]